nirsevimab
Selected indexed studies
- Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. (N Engl J Med, 2022) [PMID:35235726]
- Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: a systematic review and meta-analysis. (Lancet Child Adolesc Health, 2025) [PMID:40319903]
- Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants. (N Engl J Med, 2023) [PMID:38157500]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Nirsevimab: A Review. (2024) pubmed
- Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. (2022) pubmed
- Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: a systematic review and meta-analysis. (2025) pubmed
- Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants. (2023) pubmed
- Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. (2020) pubmed
- Nirsevimab and Hospitalization for RSV Bronchiolitis. (2024) pubmed
- RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing. (2024) pubmed
- Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity. (2022) pubmed
- Nirsevimab: First Approval. (2023) pubmed
- Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. (2023) pubmed